Logo image of PRTG

PORTAGE BIOTECH INC (PRTG) Stock Price, Quote, News and Overview

NASDAQ:PRTG - Nasdaq - VGG7185A1369 - Common Stock - Currency: USD

4.14  -0.37 (-8.2%)

PRTG Quote, Performance and Key Statistics

PORTAGE BIOTECH INC

NASDAQ:PRTG (3/3/2025, 5:20:01 PM)

4.14

-0.37 (-8.2%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High23.01
52 Week Low2.1
Market Cap6.83M
Shares1.65M
Float800.00K
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-13 2025-08-13/amc
IPO10-28 2013-10-28


PRTG short term performance overview.The bars show the price performance of PRTG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

PRTG long term performance overview.The bars show the price performance of PRTG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PRTG is 4.14 USD. In the past month the price decreased by -6.12%. In the past year, price decreased by -63.02%.

PORTAGE BIOTECH INC / PRTG Daily stock chart

PRTG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.9 373.71B
AMGN AMGEN INC 15.68 166.89B
GILD GILEAD SCIENCES INC 25.16 144.52B
VRTX VERTEX PHARMACEUTICALS INC 1666.59 124.16B
REGN REGENERON PHARMACEUTICALS 15.01 74.87B
ARGX ARGENX SE - ADR 241.32 37.83B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.41B
BNTX BIONTECH SE-ADR N/A 26.75B
ONC BEIGENE LTD-ADR N/A 26.20B
BIIB BIOGEN INC 8.6 20.65B
NTRA NATERA INC N/A 18.89B
GMAB GENMAB A/S -SP ADR 24.69 14.59B

About PRTG

Company Profile

PRTG logo image Portage Biotech Inc is a VG-based company operating in Biotechnology industry. Portage Biotech Inc. is a clinical-stage immuno-oncology company. The firm is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.

Company Info

PORTAGE BIOTECH INC

Clarence Thomas Building, P.O. Box 4649, Road Town

Tortola ONTARIO VG1110 VG

CEO: Ian Walters

Employees: 7

Company Website: https://portagebiotech.com/

Investor Relations: http://ir.portagebiotech.com

Phone: 4167377600

PORTAGE BIOTECH INC / PRTG FAQ

What is the stock price of PORTAGE BIOTECH INC today?

The current stock price of PRTG is 4.14 USD. The price decreased by -8.2% in the last trading session.


What is the ticker symbol for PORTAGE BIOTECH INC stock?

The exchange symbol of PORTAGE BIOTECH INC is PRTG and it is listed on the Nasdaq exchange.


On which exchange is PRTG stock listed?

PRTG stock is listed on the Nasdaq exchange.


What is PORTAGE BIOTECH INC worth?

PORTAGE BIOTECH INC (PRTG) has a market capitalization of 6.83M USD. This makes PRTG a Nano Cap stock.


How many employees does PORTAGE BIOTECH INC have?

PORTAGE BIOTECH INC (PRTG) currently has 7 employees.


What are the support and resistance levels for PORTAGE BIOTECH INC (PRTG) stock?

PORTAGE BIOTECH INC (PRTG) has a support level at 3.51 and a resistance level at 4.51. Check the full technical report for a detailed analysis of PRTG support and resistance levels.


Should I buy PORTAGE BIOTECH INC (PRTG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PORTAGE BIOTECH INC (PRTG) stock pay dividends?

PRTG does not pay a dividend.


When does PORTAGE BIOTECH INC (PRTG) report earnings?

PORTAGE BIOTECH INC (PRTG) will report earnings on 2025-08-13, after the market close.


What is the Price/Earnings (PE) ratio of PORTAGE BIOTECH INC (PRTG)?

PORTAGE BIOTECH INC (PRTG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-129.8).


What is the Short Interest ratio of PORTAGE BIOTECH INC (PRTG) stock?

The outstanding short interest for PORTAGE BIOTECH INC (PRTG) is 2.85% of its float. Check the ownership tab for more information on the PRTG short interest.


PRTG Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to PRTG. When comparing the yearly performance of all stocks, PRTG is a bad performer in the overall market: 87.65% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PRTG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PRTG. While PRTG seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRTG Financial Highlights

Over the last trailing twelve months PRTG reported a non-GAAP Earnings per Share(EPS) of -129.8. The EPS decreased by -403.1% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1357.19%
ROE -2830.59%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)-403.1%
Revenue 1Y (TTM)N/A

PRTG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to PRTG. The Buy consensus is the average rating of analysts ratings from 6 analysts.


Ownership
Inst Owners3.33%
Ins Owners49.21%
Short Float %2.85%
Short Ratio0.03
Analysts
Analysts43.33
Price TargetN/A
EPS Next Y99.49%
Revenue Next YearN/A